Navigation Links
Molecular 'marker' on stem cells aids research, perhaps therapies

A sugar molecule present on embryonic stem cells also has been found on the surface of a type of adult stem cell, a discovery that may help researchers isolate and purify adult stem cells for use in therapies aimed at bone healing, tendon repair and cartilage regeneration, researchers at UT Southwestern Medical Center report.

The molecule, called SSEA-4, was found on the surface of certain stem cells in bone marrow that give rise to fat, cartilage and bone. These so-called mesenchymal cells are a tiny component of bone marrow; the vast majority of bone marrow is made up of hematopoietic stem cells, which give rise to blood and immune cells.

Dr. Rita Perlingeiro, assistant professor in the Center for Developmental Biology and of molecular biology, said detecting SSEA-4 will aid in singling out the mesenchymal stem cells, or MSCs, for more detailed scientific study as well as for possible medical applications. The cells have shown promise in early clinical studies elsewhere, where scientists tested their use to repair bone defects and to attenuate the effects of bone loss in diseases such as osteoporosis.

The study is available online and will be published in the Feb. 15 issue of the journal Blood.

Although mesenchymal cells were discovered in the 1970s, researchers still use decades-old methods to isolate them from bone marrow, said Dr. Perlingeiro, who led the research.

Exploiting the sugar molecule as a biological marker will boost researchers?ability to obtain a purer, more homogeneous population of MSCs. That’s an important consideration, for example, in applications such as tissue engineering, where only bone-generating cells are needed. Such cells are being tested by a number of researchers for their ability to grow fat, cartilage and bone on special biomaterial-based scaffolding, with the goal of producing soft tissue for reconstruction or augmentation, or to shore up bones left fragile by age or disease.

“ With a purer cell population, you should have a more effective therapy,?Dr. Perlingeiro said.

The SSEA-4 molecule was known to be on the surface of embryonic stem cells, as well as on embryonic carcinoma cells, the malignant counterparts of embryonic stem cells.

Dr. Perlingeiro’s ongoing studies also suggest that the SSEA-4 molecule might be present in other tissues, leading to the intriguing possibility that the SSEA-4 molecule could be a marker for “stemness,?she said.

“The discovery of this molecule on MSCs was surprising, and is important to further our understanding of the biological nature of adult stem cells,?Dr. Perlingeiro said. “We are also interested in learning whether SSEA-4 is expressed on other stem cells, such as those for muscle.

“It could actually be useful where we see less of it, as in tissues with very few stem cells. This marker could help us separate out those rare cells more easily.?

She and her team also are investigating the SSEA-4 molecule’s relationship to cancer stem cells, those cells in a tumor that behave like stem cells in that they self-renew and maintain the cancer even if most of the tumor is destroyed by radiation or chemotherapy.

“Is the expression of this marker elevated in a tumor" If so, perhaps it might be useful to identify cancer stem cells, but we don’t know yet,?Dr. Perlingeiro said. “That would be a very beneficial application, not just for guiding therapy, but also for early cancer detection and perhaps prevention.?
'"/>

Source:UT Southwestern Medical Center


Related biology news :

1. Molecular biology fills gaps in knowledge of bat evolution
2. Molecular machine may lead to new drugs to combat human diseases
3. Molecular Motors Cooperate In Moving Cellular Cargo, Study Shows
4. Molecular models advance the fight against malaria
5. Molecular fossils uncover link between viruses and the immune system
6. Molecular thermometers on skin cells detect heat and camphor
7. Molecular messengers perform a crucial role in the ability of injured nerve cells to heal themselves
8. Molecular steps involved in the creation of gene-silencing microRNAs identified
9. Molecular miners find pain relief drugs from the sea
10. Molecular mechanism of feather formation found
11. Molecular trigger for Huntingtons disease found

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ON , June 27, 2016 /PRNewswire/ - BIOREM Inc. ... has been advised by its major shareholders, Clean Technology ... United States based venture capital ... shares of Biorem (on a fully diluted, as converted ... the disposition of their entire equity holdings in Biorem ...
(Date:6/27/2016)... N.C. (PRWEB) , ... June 27, 2016 , ... ... commercial operations for Amgen, will join the faculty of the University of ... as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
Breaking Biology Technology: